Pfizer's Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older [...]